ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
Global Intellectual Property Portfolio Expands to 74 Issued Patents
These patents protect novel innovations integral to the
“We are proud of our growing patent estate, which is particularly impressive for a company of our size. These newly issued patents reinforce ENDRA's commitment to advancing state-of-the-art thermoacoustic systems, and expand the horizons for our novel
The following three patents were issued:
-
U.S. Patent No. 11844650 (the ‘650 patent), titled “Thermoacoustic Measurement Probe,” protects a novel sleeve-type structural configuration forTAEUS that maximizes radiofrequency energy absorption and the corresponding thermoacoustic signal strength. The sleeve-type configuration also minimizes signal noise to provide a clearer thermoacoustic signal. Embodiments cited in the ‘650 patent utilize a plurality of radiofrequency feeds that enable signal polarization and lead to a clearer thermoacoustic measurement.
-
Chinese Patent No. ZL2021800757024 (the ‘024 patent), titled “Thermal Ablation System with Integrated Thermoacoustic Temperature Measurement,” relates to the
TAEUS system determining temperature at a specific location in the human body. For example, the ‘024 patent protects a system designed to monitor temperature during thermal ablation for overheating to avoid destroying healthy tissue and underheating to mitigate not destroying targeted cancerous tumor cells.
-
European Patent No. EP3902490, titled “Method and System for Monitoring Tissue Temperature,” relates to a novel method with the
TAEUS system for monitoring tissue temperature during surgical procedures, such as thermotherapy and cryotherapy.
About
Forward-Looking Statements
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213698250/en/
Company:
Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com
Investor Relations:
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Source: